SstI Polymorphism of the Apolipoprotein CIII Gene in Iranian Hyperlipidemic Patients: A Study in Semnan Province

Document Type: Original Article

Authors

1 Department of Biochemistry, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran

2 Department of Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

3 Biotechnology Research Center, Semnan University of Medical Sciences, Semnan, Iran

4 Immune and Gene Therapy Lab, CCK, Karolinska University Hospital Solna, Stockholm, Sweden

5 Department of Immunology, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran

Abstract

Objective(s)
The Sst-I polymorphic site on the 3' untranslated region of the apo CIII gene, has been previously reported to be associated with hypertriglyceridemia. The aim of the present study was to explore the association between Sst-I polymorphism with plasma lipid and lipoprotein levels in hyperlipidemic (HLP) patients from Semnan province, Iran.
Materials and Methods
Genomic DNA was prepared from 76 patients with HLP and 75 matched healthy subjects. DNA samples were amplified by polymerase chain reaction. The samples were analyzed by restriction fragment length polymorphism (RFLP) method using SstI enzyme.
Results
The genotype and allelic frequencies for this polymorphism were significantly different between HLP and normolipidemic groups (P< 0.002). Plasma triglyceride (TG) level was higher in both groups, in S2S2 genotype was more than in the S1S1and S1S2 genotypes, however, there was no significant difference in comparison with the control group. Subjects with S1S2 + S2S2 genotypes in compare to S1S1 genotype had odd ratio of 2.8 (95% CI: 1.41-5.56, P< 0.003) for developing hypertriglyceridemia.
Conclusion
The results showed that the presence of rare S2 allele was associated with change in TG level in the selected population.

Keywords


1.Groenendijk M, Cantor RM, de Bruin TWA, Dallinga - Thie GM. The apoAI-CIII-AIV gene cluster. Atherosclerosis 2001; 157:1-11.

2.Gangabadage CS, Zdunek J, Tessari M, Nilsson S, Olivecrona G,Wijmenga SS. Structure and dynamics of human apolipoprotein CIII. J Biol Chem 2008; 283:17416-17427.

3.Jong MC, Hofker MH, Havekes LM. Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999; 19:472-484.

4.Buzza M, Fripp Y, MitchellRJ. Apolipoprotein AI and CIII gene polymorphisms and their association with lipid levels in Italian, Greek and Anglo-Irish populations of Australia. Ann Hum Biol 2001; 28:481-490.

5.Voshol PJ, Rensen PC, van Dijk KW, RomijnJA,Havekes LM. Effect of plasma triglyceride metabolism on lipid storage in adipose tissue: studies using genetically engineered mouse models. Biochim Biophys Acta 2009; 1791:479-485.

6.ItoY, Azrolan N, O'Connell A, Walsh A, BreslowJL. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 1990; 249:790-793.

7.Kawakami A, Osaka M, Tani M, Azuma H, Sacks FM, ShimokadoK,Yoshida M. Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction. Circulation 208; 118:731-742.

8.Karathanasis SK, Oettgen P, Haddad IA, AntonarakisSE. Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4). Proc Natl Acad Sci U S A 1986; 83:8457-8461.

9.Garasto S, Rose G, Derango F, Berardelli M, CorsonelloA, Feraco E, et al. The study of apoA1, apoC3 and apoA4 variability in healthy ageing people reveals another paradox in the oldest old subjects. Ann Hum Genet 2003; 67:54-62.

10.Xu CF, Talmud P, Schuster H, Houlston R, Miller G, Humphries S. Association between genetic variation at the apo AI-CIII-AIV gene cluster and familial combined hyperlipidaemia. Clin Genet 1994; 46:385-397.

11.Li WW, Dammerman MM, Smith JD, Metzger S, BreslowJL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 1995; 96:2601-2605.

12.Surguchov AP, Page GP, Smith L, PatschW, BoerwinkleE. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 1996; 16:941-947.

13.Dammerman M, Sandkuijl LA, Halas JL, Chung W, BreslowJL. Anapolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3' untranslated region polymorphisms. Proc Natl Acad Sci USA 1993;90:4562-4566.

14.Brown S, Ordovas JM, Campos H. Interaction between the apoC3 gene promoter polymorphisms, saturated fat intake and plasma lipoproteins. Atherosclerosis 2003;170:307-313.

15.Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE. Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 1993; 00157-169.

16.Ko YL, Ko YS, Wu SM, Teng MS, Chen FR, Hsu TS, et al. Interaction between obesity and genetic polymorphisms in the apolipoprotein CIII gene and lipoprotein lipase gene on the risk of hypertriglyceridemia in Chinese. Hum Genet 1997; 100:327-333.

17.Hoffer MJ, Sijbrands EJ, De Man, FH, Havekes LM, Smelt AH,Frants RR. Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. Eur J Clin Invest 1998; 28:807-812.

18.Shoulders CC, Harry PJ, Lagrost L, White SE, Shah NF, North JD, et al. Variation at the apo AI/CIII/AIV gene complex is associated with elevated plasma levels of apo CIII. Atherosclerosis 1991; 87:239-2247.

19.Dallinga-Thie GM, Bu XD, Van Linde-Sibenius Trip M, Rotter JI, LusisAJ, de Bruin TW. Apolipoprotein A- I/C-III/A-IV gene cluster in familial combined hyperlipidemia: effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 1996; 37:136-147.

20.Marcil M, Boucher B, Gagne E, Davignon J, Hayden M, Genest JJ.Lack of association of the apolipoprotein A- I-C-III-A-IV gene XmnI and SstI polymorphisms and of the lipoprotein lipase gene mutations in familial combined hyperlipoproteinemia in French Canadian subjects. J Lipid Res1996; 37:309-319.

21.Price WH, Morris SW, Kitchin AH, Wenham PR, BurgonPR, Donald PM. DNA restriction fragment length polymorphisms as markers of familial coronary heart disease. Lancet 1989; 24:1407-14011.

22.Thu NN, Tuyet Mai TT, Ohmori R, Kuroki M, Van Chuyen N, Kim Hung NT, et al. Plasma triglyceride and HDL-Cholesterol concentrations in vietnamese girls are affected by lipoprotein lipase, but not apolipoprotein CIII polymorphism. J Nutr 2006; 136:1488-1492.

23.Azizi F, Rahmani M, Ghanbarian A, Emami H, Salehi P, MirmiranP, Sarbazi N. Serum lipid levels in an Iranian adult population: Tehran lipid and glucose study. Eur J Epidemiol 2003; 18:311-319.

24.Miller SA, Dykes DD, Polesky HF.A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 11;16:1215. 

25.Russo GT, Meigs JB, Cupples LA, Demissie S, Otvos JD, Wilson PW, et al. Association of the Sst-I polymorphism at the apoC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. Atherosclerosis 2001; 158:173-181.

26.Ordovas JM, Lopez-Miranda J, Mata P, Perez-Jimenez F, Lichtenstein AH, Schaefer EJ. Gene-diet interaction in determining plasma lipid response to dietary intervention.Atherosclerosis 1995; 118:S11-27.

27.Dallinga-Thie GM, Van Linde-Sibenius Trip M, Rotter JI, Cantor RM, Bu X, LusisAJ, et al. Complex genetic contribution of the apo AI-CIII-AIV gene cluster to familial combined hyperlipidemia.Identification of different susceptibility haplotypes. J Clin Invest 1997; 1:953-961.

28.Xu CF, Angelico F, Del Ben M, Humphries S. Role of genetic variation at the apo AI-CIII-AIV gene cluster in determining plasma apo AI levels in boys and girls. Genet Epidemiol 1993; 10:113-122.

29.Ordovas JM, Civeira F, Genest J Jr, Craig S, Robbins AH, Meade T, et al. Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis 1991; 87:75-86.

30.Dallongeville J, Meirhaeghe A, Cottel D, Fruchart JC, Amouye lP, Helbecque N. Gender related association between genetic variations of apoC-III gene and lipid and lipoprotein variables in northern France. Atherosclerosis 2000; 150:149-157.

31.Zeng Q, Dammerman M, Takada Y, Matsunaga A, BreslowJL, Sasaki J. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. Hum Genet 1995; 95:371-375.

32.Huang MC, Wang TN, Liu YL, Pa TH, Tu HP, Huang YC, et al. Effect of SstI polymorphism of the apolipoprotein CIII gene and environmental factors on risks of hypertriglyceridemia in Taiwan aborigines. Circ J 2006; 70:1030-1036.

33.Hong SH, Park WH Lee, CC, Song JH, Kim JQ. Association between genetic variations of apo AI-CIII-AIV cluster gene and hypertriglyceridemic subjects. Clin Chem 1997; 43:13-17.

34.Ta§ S. Strong association of a single nucleotide substitution in the 3'-untranslated region of the apolipoprotein- CIII gene with common hypertriglyceridemia in Arabs. Clin Chem 1989; 35:256-259

35.Chhabra S, Narang R, Krishnan LR, Vasisht S, Agarwal DP, Srivastava LM, et al. Apolipoprotein C3 SstI polymorphism and triglyceride levels in Asian Indians. BMC Genet 2002; 6:3:9.

36.Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, et al. Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000. J Atheroscler Thromb 2005; 12:240-250.

37.Kee F, Amouyel P, Fumeron F, Arveiler D, Cambou JP, Evans A, et al. Lack of association between genetic variations of apo A-I-C-III-A-IV gene cluster and myocardial infarction in a sample of European male: ECTIM study. Atherosclerosis 1999; 145:187-195.

38.Sarraf-Zadegan N, Sayed-Tabatabaei FA, Bashardoost N, Maleki A, Totonchi M, Habibi HR, et al. The prevalence of coronary artery disease in an urban population in Isfahan, Iran. Acta Cardiol 1999; 54:257-263.